Tuberculosis (TB) primarily results from an infection with Mycobacterium tuberculosis in the lungs and other parts of the body such as the gut. It can generally be cured with first line treatment within several months; however, TB is one of the top 10 causes of death worldwide (W.H.O.) and is a leading killer of immuno-compromised (HIV+) patients. In 2017, 10 million people were diagnosed and 1.6 million died from TB. A major challenge of TB treatment is the facile development of drug resistance, in particular to Isoniazid and Rifampicin. Below is an overview of current treatment regimens and highlighted therapies in clinical development.
Highlights in the development of new treatments targeting MDR-tuberculosis
